Novem Group Reduces Holdings in Abbott Laboratories $ABT

Novem Group reduced its stake in Abbott Laboratories (NYSE:ABT) by 61.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,126 shares of the healthcare product maker’s stock after selling 6,599 shares during the quarter. Novem Group’s holdings in Abbott Laboratories were worth $517,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Harbor Capital Advisors Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at approximately $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories during the third quarter valued at $31,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $33,000. Finally, Copia Wealth Management purchased a new position in Abbott Laboratories in the 3rd quarter worth $38,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on ABT shares. Wells Fargo & Company dropped their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Daiwa Securities Group decreased their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Evercore dropped their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Benchmark reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, BTIG Research restated a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.35.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. Corporate insiders own 0.46% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS kept a “buy” rating on ABT, signaling continued conviction in Abbott’s franchise despite trimming its price target — a vote of confidence from a major bank. UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Income-minded investors are seeing value: recent coverage highlights a dividend yield near 3% and labels ABT a “dividend king” opportunity for buy-the-dip investors. That supports demand from yield-focused funds. Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity
• Positive Sentiment: Progress on Abbott’s CancerGuard multi-cancer early-detection program and new DETECT A outcomes reinforce the company’s long-term diagnostics growth narrative. Positive clinical/award news can support upside over time. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
• Neutral Sentiment: Options-market activity is drawing attention; spikes in put/call flows can foreshadow moves but aren’t a directional confirmation by themselves. Traders may use this as a signal for volatility, not fundamentals. Is the Options Market Predicting a Spike in Abbott Laboratories Stock?
• Neutral Sentiment: Coverage notes that ABT is trading near its 52-week low while many analysts remain bullish — an outlook that supports buy-side interest if sentiment stabilizes. Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love
• Negative Sentiment: Major banks collectively trimmed price targets (multiple firm actions published), creating downward pressure on the stock as headline PT cuts refresh sell-side valuation estimates. This broad re-rating is a primary driver of today’s weakness. Mizuho Cuts Abbott Laboratories Price Target
• Negative Sentiment: UBS and Argus lowered their targets (UBS to $135; Argus to $125) even while keeping buy ratings — a mixed signal that reduces near-term upside expectations vs. prior levels. UBS Adjusts Abbott Laboratories Price Target to $135
• Negative Sentiment: Social and analyst chatter highlights that Q1 results beat estimates but management trimmed full-year guidance (diagnostics headwinds, mild flu season, acquisition costs), which triggered post-earnings selling and still weighs on sentiment. Abbott Laboratories Stock Opinions on Q1 Earnings and Guidance Cut

Abbott Laboratories Stock Down 3.3%

Shares of ABT opened at $92.83 on Wednesday. The company has a market capitalization of $161.67 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 1.60 and a beta of 0.79. Abbott Laboratories has a 52 week low of $92.65 and a 52 week high of $139.06. The stock’s 50-day moving average price is $107.21 and its 200-day moving average price is $118.00. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period last year, the business earned $1.09 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.53 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.